CClinicalTrials.gg
Not yet recruitingNCT02575469Updated Jan 24, 2017

Exercise Capacity in Diseases and Health

An observational study in Exercise Capacity, sponsored by Rambam Health Care Campus. Not yet recruiting at 1 site in Israel. Open to participants aged 6 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-24.

Sponsored by Rambam Health Care Campus · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
6 Years to 90 Years
Sex
All
01

Study summary

Exercise capacity is a key factor to evaluate and treat patients in different diseases (e.g. ischemic heart disease, chronic obstructive pulmonary disease, cystic fibrosis). The best way to measure exercise capacity is to perform a cardiopulmonary exercise testing. Normal/reference values in health and disease relate to specific population and subpopulations. The population in Israel is unique in its diversity.

Objectives: Data collection of exercise capacity assessment in health and illness in the northern of Israel for future local database.

Population: 500 Patients evaluated routinely in the exercise lab (pediatric cardiology institute) and healthy volunteers evaluated as controls.

Study design: Prospective observational study. Participants will answer a health related questioner, undergo a physical examination, perform a cardiopulmonary exercise test on a treadmill or a cycle ergometer.

Read the detailed description

Exercise capacity is a key factor to evaluate and treat patients in different diseases (e.g. ischemic heart disease, chronic obstructive pulmonary disease, cystic fibrosis). The best way to measure exercise capacity is to perform a cardiopulmonary exercise testing. Normal/reference values in health and disease relate to specific population and subpopulations. The population in Israel is unique in its diversity.

Objectives: Data collection of exercise capacity assessment in health and illness in the northern of Israel for future local database.

Population: 500 Patients evaluated routinely in the exercise lab (pediatric cardiology institute) and healthy volunteers evaluated as controls.

Study design: Prospective observational study. Participants will answer a health related questioner, undergo a physical examination, perform a cardiopulmonary exercise test on a treadmill or a cycle ergometer .

02

Conditions studied

  • Exercise Capacity
03

In context

Lead sponsor

Rambam Health Care Campus is the lead sponsor of 456 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

500 Patients evaluated routinely in the exercise lab (pediatric cardiology institute) and healthy volunteers evaluated as controls.

Inclusion criteria

  • Ability to complete full exercise evaluation (including cardiopulmonary exercise testing).

Exclusion criteria

Exclusion Criteria:

  • Acute illness on visit day.
  • for healthy volunteers: chronic disease or use of medications.
  • Professional athletes.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. VO2 (oxygen consumption)

    Time frame: 30 minutes

07

Study locations

1 site
  • RAMBAM health care center
    Haifa, 31096, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02575469
Lead sponsor
Rambam Health Care Campus
Responsible party
Prof. Avraham Lorber (Head of pediatric cardiology institute, Ruth children hospital, Rambam Health Care Campus) — Principal investigator
First posted
Oct 14, 2015
Start date
Oct 1, 2017 (estimated)
Primary completion
Oct 1, 2035 (estimated)
Completion
Jan 1, 2036 (estimated)
Last update
Jan 24, 2017

Study contacts

Abraham Lorber, MD
Contact
a_lorber@rambam.health.gov.il
+972-4-7774630
Ronen Bar-Yoseph, MD
Contact
ronenfabi@gmail.com
+972-4-777-4304

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion